Open AccessUse of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Author(s) -
Osama E. Rahma,
Greg Yothers,
Theodore S. Hong,
Marcia M. Russell,
Y. Nancy You,
William A. Parker,
Samuel A. Jacobs,
Linda H. Colangelo,
Peter C. Lucas,
Marc J. Gollub,
William A. Hall,
Lisa A. Kachnic,
Namrata Vijayvergia,
Mark Allen O’Rourke,
Bryan A. Faller,
Richard K. Valicenti,
Tracey E. Schefter,
Sagila George,
Radhika Kainthla,
Philip J. Stella,
Elin R. Sigurdson,
Norman Wolmark,
Thomas J. George
Publication year - 2021
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2021.1683
Subject(s) - medicine , folfox , capecitabine , oxaliplatin , neoadjuvant therapy , colorectal cancer , total mesorectal excision , clinical endpoint , chemoradiotherapy , surgery , regimen , oncology , randomized controlled trial , radiation therapy , cancer , breast cancer
Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As such, novel combinations are needed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom